| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Algorae Pharmaceticls Ltd (LVCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Living Cell Technologies Limited was founded in 1987 and is based in Auckland, New Zealand. The Company is an Australian biotechnology. It is engaged in the clinical development of cell-based therapeutics for the treatment of diabetes, and pre-clinical research and development into neurological disorders. The Company focuses on developing treatments for implanting healthy living cells to replace or repair disease or damaged organs, for a range of life-threatening diseases, and also focuses on a treatment for Type 1 diabetes. The Company's products include DIABECELL, NTCELL, Fac8Cell, Porcine Tissues and Encapsulation Technology. DIABECELL is a porcine insulin-producing cell product that is in Phase IIb clinical trial for the treatment of Type 1 diabetes; NTCELL is a choroid plexus cell product to treat neurodegenerative diseases; and IMMUPEL isolates the transplanted cells from the patient's immune system and eliminates the need for toxic immunosuppressant drugs.